ABSTRACT SUBMISSION GUIDELINES
- Abstracts must be submitted on the understanding that they have not been presented elsewhere (except in the form of a thesis/dissertation) and are not being considered by another conference.
- All submitted abstracts will undergo a peer-review screening process and are expected to meet the standards of academic excellence.
- One presentation (oral or poster) per officially registered participant is allowed.
- All abstracts must be written in English.
- Authors must indicate which mode (oral or poster) is preferred.
- The 38PCC and 2024 IC2 Paper Committee reserves the right to reassign modality, when necessary.
Important Dates
- 10 May 2024: Deadline for Abstract Submission
- 19 May 2024: Extended Deadline for Abstract Submission
- 31 May 2024: Extended Deadline for Abstract Submission (Posters Only)
- 27-31 May 2024: Notification of Acceptance of Abstracts
- 14 June 2024: Deadline for Registration of Authors
Format Guidelines
The structured abstract should be written in English with no more than 250 words. It should include background and objectives, methods, results, conclusions, and a maximum of six (6) keywords. Chemical nomenclature should conform to IUPAC rules and measurements should be in SI units.
Example:
| Immunotherapy using slow-cycling tumor cells prolonged the overall survival of tumor-bearing mice Author’s names Affiliation Background: Despite considerable progress in the development of anticancer therapies, there is still a high mortality rate caused by cancer relapse and metastasis. Dormant or slow-cycling residual tumor cells are thought to be a source of tumor relapse and metastasis and are therefore an obstacle to therapy. In this study, we assessed the drug resistance of tumor cells in mice and investigated whether vaccination could promote survival. Methods: The mouse colon carcinoma cell line CT-26 was treated with 5-fluorouracil to assess its sensitivity to drug treatment. Mice with colon tumors were immunized with inactivated slow-cycling CT-26 cells to estimate the efficacy of this vaccine. Results: We identified a small population of slow-cycling tumor cells in the mouse colon carcinoma CT-26 cell line, which was resistant to conventional chemotherapy. To inhibit tumor recurrence and metastasis more effectively, treatments that selectively target the slow-cycling tumor cells should be developed to complement conventional therapies. We found that drug-treated, slow-cycling tumor cells induced a more intense immune response in vitro. Moreover, vaccination with inactivated slow-cycling tumor cells caused a reduction in tumor volume and prolonged the overall survival of tumor-bearing mice. Conclusions: These findings suggest that targeting of slow-cycling tumor cells application using immunotherapy is a possible treatment to complement traditional antitumor therapy. Keywords: cancer relapse; drug resistance; slow-cycling tumor cells; tumor vaccine. |